PSI VisSIG Wonderful Wednesday Webinar Series
This is a good opportunity to develop your knowledge by thinking through a practical example, practicing how to apply graphics principles, and developing your coding skills.
PSI Book Club
PSI are running a book club! We will be reading and discussing non-technical books which are relevant to our roles.
PSI Pre-Clinical SIG Webinar: Therioepistemology - Rethinking how we conduct animal-based experimentation
In this webinar we will explore Therioepistemology: the study of how knowledge is gained from animal research, and outline six questions that help critically evaluate animal-based biomedical research from a therioepistemological perspective.
PSI Scientific Meeting: Adaptive Designs and their Application
Join us to here about some hot topics in the area of adaptive designs and associated methods. There will be a mixture of cutting edge methodology and real world applications. Along with the opportunity for plenty of discussion and sharing of ideas and opinions!
PSI Scientific Meeting: Decentralised Clinical Trials
In this event we will hear from expert speakers on the statistical and operational challenges and considerations of decentralised clinical trials, the promise of digital health data and wearable technology, as well the regulatory perspective to such studies
PSI Vaccines SIG Webinar: Assessing Population Level Vaccine Effectiveness Under Different Study Designs
This presentation provides a brief description of the herd protective effects of the oral cholera vaccines, as an example, that have been evaluated for herd protection in various study settings, leveraging the geographic information system (GIS) tools for analyses.
PSI Webinar Series: Showcasing R use in Pharma
Talks in these webinars will cover general frameworks for app development, regulatory submissions using R and case studies of using R Shiny in both operational and methodological settings.
PSI Careers - MEDMathS: Medicine Empowered by Data, Maths and Statistics
In just 1 hour, learn about the field of medical statistics and how it plays a crucial role in developing ground-breaking new medicines, vaccines and healthcare products.
Joint PSI & EFSPI HTA SIG Webinar: Statistics in EU HTA - PICOs, Estimands & More
The EU regulation on Health Technology Assessment (HTA) is coming into force from 2025! But why should pharmaceutical statisticians care? Join our webinar to find out more…
PSI Medical Statistics Careers Event
Our annual PSI Medical Statistics Careers Event, will be held in person at GSK House in Brentford, London on Wednesday 7th December 2022, and will feature live presentations from new starters, a panel discussion with industry representatives, and an exhibition session.
Special Interest Groups
The Application and Implementation of Methodologies in Statistics (AIMS)
The Benefit-Risk SIG was set up at the start of 2012 to help support those involved in this fast evolving area.
The PSI / EFSPI Biomarkers Special Interest Group has been formed with the aim of developing knowledge and opinions within the statisticians about biomarker usage and the related statistical and study design techniques that are involved.
The CSM/QTL SIG is a joint collaboration including PSI, ASA BIOP & EFSPI providing a forum to discuss strategies and methodology with other interested parties in Centralised Statistical Monitoring and Quality Tolerance Limits
Bridging Data Science knowledge and expertise across various groups and functions within the pharmaceutical industry to increase collaboration, awareness, knowledge sharing and enhance drug development. We’ll encourage the development of new statistical and machine learning methods and approaches as well as in novel applications of the well-established methods.
Sharing experiences and challenges of external patient level data sharing with particular focus on data privacy and anonymization processes.
The Quantitative Decision-making Special Interest Group (QDM SIG) was formed in October 2017. It is a group of statisticians from industry and academia, with experience and interests in statistical methods for quantitative decision-making in drug development.
What is the state of the art regarding approaches to incorporate historical data into the formal design and analysis of clinical trials, Which statistical methods should we use to make historical and current data comparable, What are the regulatory requirements necessary for the acceptance of historical data in drug approval?
The purpose of the Healthcare Technology Assessment SIG is to provide statisticians working in the Pharmaceutical Industry engaged in Health Technology Assessments, and others in related fields of research...
Launch & Lifecycle ESIG
Providing a platform for statisticians from sponsors and CROs to working in the launch and lifecycle management (including traditional medical affairs area,
This SIG will connect the following two topics: general biostatistics Neuroscience community, and working groups on estimands & other topics in Neuroscience.
The draft addendum of the ICH E9 guideline on Statistical Principles for Clinical Trials was released in August 2017 and introduced an estimand framework. In February 2018, Evgeny Degtyarev from Novartis and Kaspar Rufibach from Roche started an informal working group to discuss how to implement the draft addendum in oncological clinical trials.
To provide a forum to discuss the statistical issues involved in Regulatory and Investigative Toxicology.
The regulatory SIG co-ordinates regulatory activities across the European Pharmaceutical Statistical community and to engage with European Regulatory statisticians.
A special interest group to increase collaboration and enhance awareness of strategies and methodologies applied in the utilization of Real World Data in the pharmaceutical industry.
The SIG “Small populations” provides a forum for identifying and discussing statistical methodology related to clinical development of treatments in small populations, and for sharing experiences.
Subgroup analysis is routinely conducted in drug development, in various settings; one key aspect is the regulatory requirement to demonstrate consistency of treatment effect across a pre-defined set of subgroups (e.g., ICHE5, E9, E17).
Creating a professional platform for statisticians in the Pharmaceutical industry, Regulatory agencies and Public Health organizations working on the research and development of vaccines to understand how best to apply methodologies.
Effective visualisation of data should belong to the core skills of statisticians as it represents an essential tool in exploring data as well as explaining data.